NOVEMBER 2025

🌿 BAC Office | November NewsletterSupporting Hawaiʻi’s Behavioral Health Providers with Care & Aloha 🧠 Industry Highlights & Updates1. Telehealth Coverage ContinuesTelehealth remains reimbursable across most Hawaiʻi Medicaid and commercial plans. Many payers cite its importance for access on neighbor islands and rural communities. Tip: Ensure correct POS and modifier usage to prevent denials. BAC Office can help verify guidelines by payer. 2. New 2025 Behavioral Health Codes (Coming Soon)
3. Credentialing & Compliance Reminders
Billing Tip: Always verify the member’s line of business before submitting claims. For example, when working with Ohana, a patient may be enrolled in multiple plans, such as:
Billing Tip: Always confirm whether the member is enrolled in QUEST Integration vs commercial lines before billing to avoid recoupments. 🍂 Thanksgiving Schedule & AppreciationWe are incredibly thankful for all of our clients, partners, and providers across Hawaiʻi. Your commitment to community care inspires us every day. BAC Office will be closed: 🦃 Thanksgiving Medical Humor:
BAC Office |

HMSA Federal Plans-Gender Identity Services Exclusion for Federal Plans
Beginning Jan. 1, 2026, surgical or chemical regimen (hormone treatments) for Sex-trait Modification to treat diagnosed gender dysphoria won’t be a covered benefit for HMSA Federal Plan 87, HMSA Plan for Postal Service Employees, and Federal Employee Program.
Members age 19 and older who received covered services or were mid-treatment in 2025 may seek a benefit exception to continue care for treatment in 2026.

The benefit exception will need review and approval by the plan before services are rendered. Providers will need to complete the Prior Authorization Form.
Available at hmsa.com/help-center/submitting-a-precertification-request/.
Refer to prc.hmsa.com/s/ for Gender Identity Services, Gender Affirming Surgery, and Gender Dysphoria articles for Federal Programs.

HMSA/Magellan Behavioral Health Clinical Practice Guidelines:– Neuropsychological Testing:
a. Removed the exclusion for testing performed when abnormalities of brain function are not suspected.
b. Removed the exclusion for testing primarily for diagnosing Attention Deficit Hyperactivity Disorder (ADHD) considering the current prevalence stimulant misuse and in support of the additional information testing may provide vs. screening tools and behavioral rating scales to confirm a diagnosis of ADHD.
c. Revised the exclusion for testing for candidacy for medical/surgical procedures when testing doesn’t inform treatment, care of behavioral health issues.
